Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE.
Cellectar Biosciences is back in focus after its fair value estimate was reset from US$76.00 to about US$10.33, a sharp shift that lines up more closely with the latest US$10 analyst price target. Recent research commentary links this change to a mix of optimism around that US$10 target and caution about how the company delivers against the assumptions behind it. As you read on, you will see how this evolving price target story shapes the broader narrative around Cellectar Biosciences and what it could mean for your watchlist.
What Wall Street Has Been Saying
🐂 Bullish Takeaways
-
Ladenburg assumed coverage of Cellectar Biosciences with a Buy rating and a US$10 price target, which aligns closely with the latest fair value reset and supports the current analyst consensus around that level.
-
The reiterated US$10 target from Ladenburg suggests some analysts see room for Cellectar Biosciences to execute against its current plan if key assumptions hold.
🐻 Bearish Takeaways
-
Roth Capital lowered its price target for Cellectar Biosciences by US$3, signaling concern about how prior expectations compared with updated assumptions around the story.
-
The combination of a reduced target from Roth Capital and the fair value cut to about US$10.33 highlights that execution risks and valuation sensitivity remain central issues for Cellectar Biosciences.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!
We've flagged 3 risks for Cellectar Biosciences. See which could impact your investment.
What's in the News
-
Cellectar Biosciences reported updated 12 month follow up data from its Phase 2b CLOVER WaM trial in relapsed or refractory Waldenström macroglobulinemia, meeting its primary endpoint with a 61.8% major response rate in 55 patients and a median response duration of 17.8 months, which the company described as supporting an accelerated regulatory pathway.
-
The company plans a confirmatory randomized study in post first line, post BTKi Waldenström macroglobulinemia with progression free survival as the expected primary endpoint and is preparing potential regulatory submissions in the United States and Europe based on the CLOVER WaM dataset.
-
Cellectar Biosciences announced acceptance of multiple iopofosine I 131 data presentations at the American Society of Clinical Oncology Annual Meeting, including a poster on outcomes after BTK inhibitor therapy in Waldenström macroglobulinemia, with further analyses planned for future medical congresses.
-
The company raised about US$30.7m through a follow on equity offering and concurrent private placement involving common stock, pre funded warrants and milestone based tranche warrants, with participation from institutional investors and executive management and the addition of an investor representative to the board.
How This Changes the Fair Value For Cellectar Biosciences
-
Fair value moved from US$76.00 to about US$10.33, aligning more closely with the latest US$10 analyst target.
-
Assumed revenue growth shifted from about 188.49% to a very large level of roughly 3.55x.
-
Net profit margin input changed from about 10.89% to roughly 18.92%.
-
Future P/E multiple moved from about 185.57x to roughly 6.43x.
-
The discount rate moved from 7.13% to about 7.26%.
Never Miss an Update: Follow The Narrative
Narratives connect Cellectar Biosciences' clinical and business story to a financial forecast and fair value anchored in analyst assumptions. They refresh as new trial data, regulatory updates and financing developments come through.
Head over to the Simply Wall St Community and follow the Narrative on Cellectar Biosciences to stay up to date on:
-
How iopofosine I 131 in Waldenström macroglobulinemia could move from Phase 2b data into conditional and accelerated approval filings in Europe and the U.S.
-
Progress on the confirmatory Phase III trial in a larger second line post BTKi setting and the expansion of the pipeline into multiple myeloma, lymphoma, pediatric glioma and triple negative breast cancer.
-
Key risks around funding needs, regulatory decisions on iopofosine, execution of the Phase III program and competition from larger radiopharmaceutical companies.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include CLRB .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
